Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transition

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    359 result(s) found for: Transition. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-003503-39 Sponsor Protocol Number: ABR54654 Start Date*: 2016-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
    Medical condition: Individuals at Ultra High Risk for Psychosis
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-001573-28 Sponsor Protocol Number: Uni-Koeln-320 Start Date*: 2007-11-26
    Sponsor Name:Universität zu Köln
    Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.
    Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004756-11 Sponsor Protocol Number: EP0009 Start Date*: 2020-01-08
    Sponsor Name:UCB Pharma SA
    Full Title: A multi-center, open-label, uncontrolled, long-term, extension study to evaluate the safety and efficacy of Lacosamide as adjunctive therapy in Japanese and Chinese adults with partial-onset seizur...
    Medical condition: Partial Onset Seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004422-31 Sponsor Protocol Number: FKS518-002 Start Date*: 2021-02-23
    Sponsor Name:Fresenius Kabi SwissBioSim GmbH
    Full Title: A Double-blind, Randomized, Multicenter, Multiple-dose, 2-arm, Parallel-group Study to Evaluate Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 - Proposed Biosimilar to Denosumab w...
    Medical condition: Osteoporosis in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10005992 Bone metabolism disorders HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-002782-35 Sponsor Protocol Number: A18-15331 Start Date*: 2019-09-19
    Sponsor Name:Aprea Therapeutics AB
    Full Title: A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
    Medical condition: Myelodysplastic Syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002041-38 Sponsor Protocol Number: SafE-OrBi Start Date*: 2019-07-29
    Sponsor Name:AZ Maria Middelares
    Full Title: Evaluation of the Safety and Effectiveness of switching from Originator (Humira®) to Biosimilar (Imraldi®) adalimumab in Flanders (SafE-OrBi)
    Medical condition: Inflammatory Bowel Diseases (Crohn's disease and Ulcerative Colitis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10021184 IBD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005004-13 Sponsor Protocol Number: NEURAPRO-E FINAL Protocol Start Date*: 2010-10-14
    Sponsor Name:Orygen Research Centre
    Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...
    Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002202-20 Sponsor Protocol Number: 213400 Start Date*: 2020-12-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Dise...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018022-30 Sponsor Protocol Number: R092670SCH3010 Start Date*: 2010-11-05
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully ...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) GB (Completed) SE (Completed) DK (Completed) IT (Completed) LV (Completed) AT (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001442-15 Sponsor Protocol Number: CFTY720D2324 Start Date*: 2011-08-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from...
    Medical condition: relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) ES (Completed) GR (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) HU (Completed) SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003127-11 Sponsor Protocol Number: CQVA149A3401 Start Date*: 2014-02-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-d...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) LV (Completed) IE (Completed) SE (Completed) AT (Completed) PT (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) HU (Completed) PL (Completed) ES (Completed) DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2015-004835-10 Sponsor Protocol Number: R092670SCH3015 Start Date*: 2016-03-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10039636 Schizophrenia simple PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) DK (Completed) GR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005972-42 Sponsor Protocol Number: 27571 Start Date*: 2007-06-12
    Sponsor Name:Merck Serono International SA
    Full Title: A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Int...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005507-41 Sponsor Protocol Number: NV18210 Start Date*: 2007-01-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ...
    Medical condition: genotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kg
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) SE (Completed) DE (Completed) BE (Completed) DK (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000007-18 Sponsor Protocol Number: GlaxoSmithKline, SCO100470 Start Date*: 2004-06-30
    Sponsor Name:GlaxoSmithKline AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel Group, 24 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/250mcg with Salmeterol 50mcg ...
    Medical condition: Study is to be conducted in patients with COPD whose airflow limitation, in terms of percentage of predicted FEV1 is between 50-80% normal.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004427-20 Sponsor Protocol Number: CHHEF Start Date*: 2020-02-07
    Sponsor Name:Luis Puente Maestu
    Full Title: PHASE IV, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, CROSSOVER, PLACEBO-CONTROLLED STUDY, TO INVESTIGATE THE EFFECT OF DUAL BRONCHODILATION WITH UMECLIDINIUM VILANTEROL ON PATIENTS WITH COPD, HYPERIN...
    Medical condition: Chronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10013108 Disease obstructive lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006840-20 Sponsor Protocol Number: 0468E8-4500 Start Date*: 2009-11-20
    Sponsor Name:Wyeth Pharmaceuticals Inc
    Full Title: Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients. Transición programada a un tratamiento basado en sirolimus frente a la continu...
    Medical condition: Renal function in kidney transplant Función renal en trasplantados renales
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001328-17 Sponsor Protocol Number: IMIB-HTF-2021-01 Start Date*: 2021-09-23
    Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia
    Full Title: Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1.
    Medical condition: Colorectal cancer and triple negative breast cancer patients (TNBC) who shown overexpression of fascin1 in the diagnostic biopsy tissue.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001764-11 Sponsor Protocol Number: PTC124-GD-030-DMD Start Date*: 2020-01-21
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
    Medical condition: nonsense mutation dystrophinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10059117 Becker's muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003715-94 Sponsor Protocol Number: IDEAL Start Date*: 2020-12-17
    Sponsor Name:Institute for Clinical and Experimental Medicine
    Full Title: INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:24:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA